MELISSA DENNY: Open Payments
NPI 1902548480 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,541 in 43 payments from 14 companies in 2025. Trend: 2023 $14 · 2024 $1,450 · 2025 $1,541
Food & beverage: $1,541
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $240 |
| Merck Sharp & Dohme LLC | 8 | $237 |
| Travere Therapeutics, Inc. | 4 | $202 |
| Novo Nordisk Inc | 4 | $172 |
| AstraZeneca Pharmaceuticals LP | 3 | $151 |
| Calliditas Therapeutics US Inc. | 6 | $132 |
| Vifor Pharma, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Ardelyx, Inc. | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: PREVYMIS, Ozempic, TARPEYO, LOKELMA, Filspari, Veltassa, TAVNEOS, KRYSTEXXA.
Industry payments across TX — which companies pay providers there.
